

# DigiOnco: A Pipeline to Unveil Digital Non-Invasive Biomarkers from Multi-parametric Radiomics Footprints

Santhi Natarajan, Anand Ravishankar, Bharathi Malakreddy A<sup>a</sup>, G.Lohith, Kritika Sekar, Shivakumar Swamy, Kumar Kallur, Basavalinga Ajai Kumar, Mahesh Bandimegal, Krithika Murugan<sup>b</sup>

<sup>a</sup>BMS Institute of Technology and Management, Visweswaraiah Technological Univesity, Bangalore, India

<sup>b</sup>Health Care Global Hospitals, Bangalore, India

---

## Abstract

**Background:** Digital Imaging and Analytical Models (DIAMs) assisted Radiomics has emerged as a promising tool towards offering personalized therapeutics to patients. Oncological researchers seem to have benefited the most from the automated and reproducible analytics that DIAMs offer. However, statistical deductions and associations of inferences from DIAMs have to be cross-validated with a higher rate of concordance and robustness. With the amount of digital healthcare data amounting to 2314 Exabytes as on date, there is a dire need for standardization of DIAMs applied to cohort based study with heterogeneous patient centric parameters, including age, phenotypes and genotypes.

**Methods:** DigiOnco, a novel pipeline, intricately woven with carefully chosen set of Machine Learning (ML) algorithms. DigiOnco unveils the digital non-invasive biomarkers from multi-parameteric Radiomics footprints obtained from the PET/CT imaging techniques. The hypothesis generation and validation is performed as both internal cross-validation as well as a retrospectively validated study on an independent cohort, having a set of external and independent group of patients.

**Findings:** The DigiOnco a pipeline consists of multidisciplinary stages with involvement of both Radiomics and modern statistics. While Radiomics provides a real-world application based avenue, statistical tools were used to narrow down our biomarker search process. offers accuracy levels ranging from 72.7% to 93.25%. The hypothesis generation and validation of derived digital biomarkers are done both as internal cross validation as well as a retrospectively validated study on an independent cohort.

**Interpretation:** Considering the integration of our current findings with follow-up studies branching into other medical sub-doamins, the potential of homogenizing Machine Learning with data intensive fields is huge. The aim of condensing the number of features is to preserve the features with the highest level information embedded in them. However it must also be duely noted that this pipeline is quite delicate when it comes to producing results as the errors encountered in each step are rippled onto the next stages. Furthermore an increased sample dataset size could help further fine tune the model. Additional Deep Learning frameworks can also be introduced to provide competition to the incumbent design model.

**Funding:** Vision Group of Science and Technology, Government of Karnataka, India

**Keywords:** Non-invasive biomarkers, Radiomics, PET/CT imaging, Machine Learning

## 1. Introduction

### 1.1. *Personalized Therapeutics: An overview*

Personalized medicine, diagnostics and therapeutics upholds the promise of accurate decision making by leveraging the power of machine learning/deep learning based Digitized Imaging and Analytical Models (DIAM). An unprecedented paradigm shift is trending in the ease with which the medical fraternity embraces DIAMs. Promising collaborations have strengthened interactions among medical specialists and technological research groups, resulting in automated and reproducible analytics, more specific in the area of oncological research. The higher levels of concordance, ability to deduce image patterns not visible to the trained human eye, along with reduced intra and interobserver variations and subjectivity, have emerged as promising catalysts for embracing DIAMs.

### 1.2. *Tumor Heterogeneity in Oncological Research: The Real Challenge for DIAM*

Tumor heterogeneity, involving a wide range of morphological phenotypes and prognostic variables, has been a great challenge in oncological diagnostics and prognosis. For example, in the much studied vertical of breast carcinoma, therapeutic decision making involves multi-modal analytics, including characterizing the morphology and grading a tumor, histopathology, immunohistochemistry (IHC) and insitu hybridization (ISH). The biomarkers thus obtained, are evaluated clinically and analytically for their optimal clinical application. The profiling is further guided by the higher rate of concordance and robustness. With the multiparametric molecular assays being very expensive, approximate mutigene testing and surrogate definitions of intrinsic subtypes can be arrived at using IHC measurements.

### 1.3. *Radiomics Assisted Digitization: An aid for Oncological Decision Making amidst heterogeneity*

With the wide-spread know how of computed tomography (CT), positron emission tomography (PET), and magnetic resonance imaging (MRI) imaging methods, Radiomics gathered much attention in the last few years of oncological research. Radiomics pipelines study the quantitative features of the image under consideration, by extracting the first-order, second-order and higher order statistical features of the Region of Interest (ROI). The hypothesis states that when a simultaneous study of heterogeneous groups of parameters of a single lesion is performed, a filtered, appropriate and customized subset of parameters (called digital biomarkers) across groups might emerge. These digital biomarkers which define specific indicative tissue characteristics, when combined with the clinical biomarkers, have the long-standing potential to offer personalized therapeutics to the patient.

### 1.4. *DIAM for Oncology: State-of-the-Art*

The stability and reproducibility of the existing Radiomics model, along with a need to standardize the assessment of digital biomarkers and cross-validation techniques, are indeed a matter that needs immediate attention before including them in the diagnostic routine. Moreover, statistical associations are, to a greater extent, confounded by the patient centric parameters like age, sex, habits, phenotypes and genotypes, that can have a profound impact on the model performance. Existing Radiomics models, as presented in Table are predominantly applied to MRI imaging, due to its monochrome image quality and wide availability of literature in terms of statistical image analytics.

The predominant issue in reproducing and comparing results across multiple studies stems from the challenge of having enriched data. Having a common data gathering point can provide an extensive and accurate comparison of different studies conducted till date. This need-of-the-hour problem needs to be dealt with a collaborative approach. As per a 2020 Stanford study, the amount of healthcare data including the Radiomics and Radiogenomics analytics data is growing at a steady rate of 48% which indicates the opportunity for collaboration. s

### *1.5. DigiOnco: A Pipeline to Unveil Digital Non-Invasive Biomarkers from PET/CT scans*

In this paper, we present DigiOnco, a novel pipeline, intricately woven with carefully chosen set of algorithms. DigiOnco unveils the digital non-invasive biomarkers from multi-parametric Radiomics footprints obtained from the PET/CT imaging techniques. The hypothesis generation and validation is performed as both internal cross-validation as well as a retrospectively validated study on an independent cohort, having a set of external and independent group of patients.

## **2. Methods**

DigiOnco based imaging analytics in cancer care holds immense potential to unlock valuable clinical insights from an abundance of patient imaging records, aided by sophisticated modeling, which will lead to deeper personalization of cancer treatment and in-turn improved outcomes. With the huge deluge in imaging data, it becomes increasingly hard to translate all these data into knowledge and subsequently leverage that knowledge to guide clinical decisions. The oncologist is overwhelmed with scientific literature, swiftly evolving treatment techniques and the exponentially increasing amount of clinical data. To provide high-quality individualized treatments, oncologists need help translating all these data into knowledge that supports decision-making in routine clinical practice by developing biomarkers (blood, tissue, imaging etc) to predict and prognosticate cancer treatment strategies. Breast cancer is high in intratumoral heterogeneity, with obvious differences in responses of different molecular subtypes to surgery, radiation or chemo-hormonal treatments. Therefore, recognizing imaging markers directly to distinguish molecular subtypes without invasive biopsies would help in guiding treatment plans for breast cancers. DigiOnco will effectively improve sensitivity and specificity of breast cancer diagnosis from PET-CT imaging phenotypes, with the help of quantitative imaging characterization. This method can support comprehensive evaluation of heterogeneity of the lesions and predict the prognosis in advance. DigiOnco based radiomic analysis of biological characteristics can effectively differentiate different subtypes of breast cancer with good accuracy and this approach could serve as a more convenient and non-invasive biomarker for the prediction of breast cancer subtypes. The pipeline developed for this project has been depicted in Figure 1.

### *2.1. Obtaining Raw data*

In order to obtain distinct yet comparable subjects, an Indian breast cancer cohort with multiple molecular subtypes of 89 patients was selected in this study. The dataset consisted of four intrinsic molecular subtypes of breast cancer which are contrasted on the genes a cancerous cell expresses. The dataset has been described in Table 1.

For each of the patient, a CT scan was conducted to obtain cross-sectional images of the hypothesised tumor location. CT scans provide a more detailed description of the patients condition by increasing the radiation level the patient is exposed to. Once the scan is completed three views




Figure 1: Project Pipeline

are obtained namely, Axial, Sagittal and Coronal. DICOM (Digital Imaging and Communication in Medicine) images were obtained after the scan. For each patient 323 new studies were conducted with each study have 384 series which corresponded to 466 instances or images of the scan. Even though DICOM files are a standard format for medical imaging, NRRD (Nearly Raw Raster Data) files are anonymized and contain no sensitive patient information in a more compact scheme.

## 2.2. Convert to a suitable format

As mentioned previously, NRRD provides a more insightful approach to understanding medical imaging and recognizing inherent patterns in a concised format. The conversion was done with the help of the Plastimatch tool which is an open source software for image computation. Plastimatch takes the DICOM image which is described in a polyline vectorized format, and converts it into a series of pixels which is more prominently known as rasterization. The subroutine for rasterization of a DICOM image set with coordinates  $x$  and  $y$  is shown below.

```
def rast(x, y, shape):
    nx, ny = draw.polygon(x, y, shape)
```

Table 1: Data Description

Subtype	Number of patients	Estrogen Receptor	Progesterone Receptor	HER2	KI67 range
Luminal A	29	+	+/-	-	[5,20]
Luminal B	36	+	+/-	+/-	[25,80]
Triple Negative(TN)	19	-	-	-	[20,90]
HER	5	-	-	+	[30,50]

```

nrrd = np.zeros(shape, dtype=np.bool)
nrrd[ny, nx] = True

return nrrd

```

### 2.3. Obtaining Radiomics Features

Information extraction from images directly has certain drawbacks. For eg, consider tumor classification using a standard Convolutional Neural Network (CNN). The CNN might be extremely successful in determining the existence of a blob of mass and its exact location. However diagnosing the exact nature and feature set of the tumor is extremely difficult for a CNN as it views the image as simply a collection of pixels without any regard to the information embedded in the image.

To tackle this issue, we have utilized radiomics based algorithms to extract feature sets from the medical images to reveal hidden characteristics. The open-source Python library, PyRa-




Figure 2: Data-Flow

diomics was used to mine out the required feature set. Before the actual extraction could be performed, a set of filters were applied on the NRRD to provide a comprehensive view of the data. The filters applied are listed in table 2.

PyRadiomics obtains radiomics features from the CT scan results in a stagewise manner. Initially the images are loaded into the platform by using SimpleITK which supports a gamut of image types along with basic image processing techniques. In the next step, the filters described in 2 are applied using SimpleITK, PyWavelets, and Numpy. Finally, statistical and texture classes are used for feature extraction. The features so obtained, are stored in a dictionary format which suitable labels.

To define a Region of Interest (ROI) and to check the dimensional constraints of the data, a mask file is utilized. The mask file contains the tumor's location demarcated by a radiologist. The features extracted are described by the Imaging Biomarker Standardization Initiative (IBSI) and have been shown in tables 3 and 4.

Therefore for each patient, the total number of features obtained are number of filters  $\times$  number of features i.e.,  $17 \times 100 = 1700$  features. Once the entire feature set has been collected, the classification task can be started.

#### 2.4. Applying Pre-processing Techniques

From the 1700 features collected, not all of the features will contribute equally in the classification function. The process of preparing the input data for pattern learning by removing redundant characteristics, reducing noises and normalizing, selecting, and extracting features is termed as Data Pre-Processing. Multiple data pre-processing techniques have been applied to the feature set. These techniques have been described in Table 5.

Since the number of test subjects for each class is not similar, a threshold confidence level must be specified during the hypothesis testing phase. A 'P-value' is utilized in hypothesis testing to test the hypothesis under observation. A lower p-value corresponds to a higher confidence level in the predictions. The number of features selected after the pre-processing step is directly proportional to the p-value as a higher p-value will be more accommodating of even unimportant features. A grid for different p-values was created and the corresponding number of features were obtained.

#### 2.5. Model-based Predictions

Once the features have been narrowed down, the model building process begins. For any task on hand, we have a wide array of classifiers which accurately predict the nature of the test

Table 2: Applied Filters

Filter	Description	Equation
Wavelet	Selective emphasizing de-emphasizing of image	-
Square	Square the image intensities	$x := (cx)^2$
Square Root	Compute root of image intensities	$x := \sqrt{cx}$
Laplacian of Gaussian	Applies a Laplacian of Gaussian filter for a $\sigma$ value	$\frac{1}{(\sigma\sqrt{2\pi})^3} e^{-\frac{x^2+y^2+z^2}{2\sigma^2}}$
Logarithm	Computes the natural logarithm of image intensities	$\text{clog}(x + 1)$
Exponential	Computes the exponential of the original image	$e^{cx}$
Gradient	Computes the gradient of the image	-

set. The set of classification algorithms considered are shown in Table 6. In order to determine which algorithm would perform the best for our cohort dataset, we trained all the models on a standard benchmark dataset belonging to the same field i.e, the Winconsin Breast Cancer Diagnostic Dataset. The tabulated results for each algorithm is shown in Table 7.

As determined, SFORCE (post validation) provides promising results without overfitting and hence is used to classify test subjects into the target classes. SFORCE establishes a symbiotic relation between a predictive model (Random Forest) and an Ensemble model (AdaBoost). Both these models work on the presented data simultaneously, aiding each other in the prediction process. Random Forests provides a strong learning system with the occasional pitfall of overfitting. The data is classified based the features which contrast the classes with the highest information content. The process of data classification using Random Forest is shown in Algorithm 1. AdaBoost solves the problem of overfitting by presenting the system with the misclassified data and forcing it to improve the overall performance. The two flavours of AdaBoost i.e, SAMME and SAMME.R have been descibed in Algorithms 2 and 3. SFORCE combines the strength of Ran-

Table 3: Features-I

Feature Class	Feature	Feature Class	Feature
Shape	Max_2D.Diameter.C Max_2D.Diameter.R Max_2D.Diameter.S Max_3D.Diameter Mesh.Volume Minor.Axis.Length Sphercity Surface.Area Surface.Volume Voxel.Volume Elongation Flatness Least.Axis.Length Major.Axis.Length	Grey Level Co-occurrence Matrix	Autocorrelation Cluster.Prominence Cluster.Shade Cluster.Tendency Constrast Correlation Difference.Average Difference.Entropy Difference.Variance Inverse.Variance Joint.Average Joint.Energy Joint.Entropy MCC Maximum.Probability Sum.Average Sum.Entropy Sum.Squares Id Idm Idn Idmn Imc1 Imc2
First Order Statistics	10 Percentile 90 Percentile Energy Entropy Interquartile.Range Kurtosis Maximum Mean.Absolute.Deviation Mean Median Minimum Range Robust.Mean.Deviation Robust.Mean.Squared Skewness Total.Energy Uniformity Variance	Grey Level Run Length Matrix	Normalized.Uniformity Variance High.Run.Emphasis Long.Run.Emphasis Long.High.Run.Emphasis Long.Low.Run.Emphasis Low.Run.Emphasis Run.Entropy Run.Uniformity Normalized.Uniformity Run.Percentage Run.Variance Short.Run.Emphasis Short.Run.High.Emphasis Short.Run.Low.Emphasis Uniformity

dom Forests and takes care of the drawbacks by using a Boosting algorithm to make the search process more concentrated as shown in Algorithm 4.

To obtain digital bio-markers, two cases studies were conducted from the available cohort dataset. The first study involved classifying test subjects as TN or non TN subjects. In the second study, the Luminal-B dataset was set aside as the test dataset due to the close resemblance of its characteristics with those of Luminal A. The model was trained to place the test subjects into the Luminal-A class with an accuracy of 72.7%. The results for different p-values have been described in Tables 8 and 9. Based on these results, box-plots have been obtained for the selected

Table 4: Features-II

Feature Class	Feature
Grey Level Size Zone Matrix	Non.Uniformity
	Non.Uniformity.Normalized
	Variance
	High.Zone.Emphasis
	Large.Area.Emphasis
	Large.Area.High.Level.Emphasis
	Large.Area.Low.Level.Emphasis
	Low.Zone.Emphasis
	Zone.Non.Uniformity
	Zone.Non.Uniformity.Normalized
	Small.Area.Emphasis
	Small.Area.High.Level.Emphasis
	Small.Area.Low.Level.Emphasis
	Zone.Entropy
	Zone.Percentage
	Zone.Variance
Gray Level Size Zone Matrix	Dependence.Entropy
	Dependence.Non.Uniformity
	Dependence.Non.Uniformity.Normalized
	Dependence.Variance
	GL.Non.Uniformity
	GL.Variance
	High.Emphasis
	Large.Dependence.Emphasis
	Large.Dependence.High.Emphasis
	Large.Dependence.Low.Emphasis
	Low.Emphasis
	Small.Dependence.Emphasis
	Small.Dependence.High.Emphasis
	Small.Dependence.Low.Emphasis
Neighbouring Gray Tone Difference Matrix	Busyness
	Coarseness
	Complexity
	Contrast
	Strength

Table 5: Preprocessing techniques

Method	Description
Missing Value Ratio	Removal of data columns where the number of missing values $\geq$ threshold
Low Variance Filter	Removal of normalized data columns where the variance $\leq$ threshold
Highest correlation filter	Removal of data columns which are highly correlated leading to redundancy
Principle Component Analysis	Transformation of data to maximize $\sigma^2$ under constraints
Fast Independent Component Analysis	Decomposition of signals to focus on mutual independence of data
Factor Analysis	Generating a common feature by reducing number of common variables



Table 6: Algorithms for traditional and ensembled classification and regression

Index	Algorithm Name	Class	Purpose
CT1	Bagged Decision Tree	Traditional	Classification
CT2	Balanced Bagged Decision Tree	Traditional	Classification
CT3	Bagged Random Forest	Traditional	Classification
CT4	Balanced Bagged Random Forest	Traditional	Classification
CT5	Decision Tree	Traditional	Classification
CT6	K-Nearest Neighbours	Traditional	Classification
CT7	Neural Network	Traditional	Classification
CE1	AdaBoost with Decision Tree	Ensemble	Classification (SR)
CE2	AdaBoost with Decision Tree	Ensemble	Classification (S)
CE3	AdaBoost with SVM	Ensemble	Classification (SR)
CE4	AdaBoost with SVM	Ensemble	Classification (S)
CE5	RUSBoost with Decision Tree	Ensemble	Classification (SR)
CE6	RUSBoost with Decision Tree	Ensemble	Classification (S)
CE7	RUSBoost with Random Forest	Ensemble	Classification (SR)
CE8	RUSBoost with Random Forest	Ensemble	Classification (S)
CE9	RUSBoost with SVM	Ensemble	Classification (SR)
CE10	RUSBoost with SVM	Ensemble	Classification (S)

Table 7: Performance Analysis

Model	CT1	CT2	CT3	CT4	CT5	CT6	CT7	CE1	CE2
Accuracy Reading	0.9917	0.9870	0.9959	0.9959	0.9651	0.9949	1.0000	0.8713	0.9709
Time Taken	44.2017	44.2017	27.9943	27.9943	15.5171	18.6339	26.5288	127.2628	127.2628
Model	CE3	CE4	CE5	CE6	CE7	CE8	CE9	CE10	SFORCE
Accuracy Reading	1.0000	1.0000	0.9870	0.9896	1.0000	0.9977	0.9920	0.9977	<b>0.9974</b>
Time Taken	54.6694	54.6694	156.7184	156.7184	24.2733	24.2733	27.1538	27.1538	<b>570.5684</b>

features which act as bio-markers for future reference.

### 2.6. Role of source funding

The funders had no role in study design, data interpretation, writing of the manuscript, and decision to submit. All the authors had full access to all the data used in the study and had final responsibility for the decision to submit for publication.

## 3. Results and Conclusion

From the data-driven pipeline, quantifiable digital biomarkers were obtained in the form of box and whisker plots. These plots provide a convinient method of displaying the data distribution

Table 8: TN vs Non-TN

P-Value	Number of Features	Accuracy (SAMME)	Accuracy (SAMME.R)
1	20	81.25	90.39
0.5	16	90.39	93.25
0.1	6	75	81.25

Table 9: HER vs Luminal-A vs TN

P-Value	Number of Features	Accuracy (SAMME)	Accuracy (SAMME.R)
1E-5	16	72	63.63
1E-6	15	70	72.7
1E-7	13	72.7	70

---

**Algorithm 1 : Ensemble Learning: Random Forest**

---

```
1: // Input: Data Set  $D = \{(x_1, y_1), (x_2, y_2), \dots, (x_m, y_m)\}$ , Feature Set  $F$ , Randomization Factor  $R$ , Number of trees  $T$ 
   // Output: Root node of  $i^{\text{th}}$  tree
2: -----
3: for  $\forall i \in \{1, 2, \dots, T\}$  do
4:    $N_i \leftarrow$  Root node of  $i^{\text{th}}$  tree
5:   if All targets belong to same class i.e  $y_i$  or  $F \in \emptyset$  then
6:     Return  $N_i$ 
7:   end if
8:    $D_i \leftarrow$  bootstrapped sample from  $D$ 
9:   for Each node do
10:     $f \leftarrow$  Randomly selected  $R$  features from  $F$ 
11:     $N_f \leftarrow$  Best Feature from  $f$  features
12:     $N_p \leftarrow$  Best Split based on  $N_f$ 
13:  end for
14: end for
15: return  $N_i$ 
```

---

---

**Algorithm 2 : Stagewise Additive Modeling: SAMME**

---

```
1: // Input: Data Set  $D = \{(x_1, y_1), (x_2, y_2), \dots, (x_m, y_m)\}$ , Number of Learning Rounds  $T$ , Learning Algorithm  $\epsilon$ 
2: // Output:  $\text{sign}(\sum_{t=1}^T \alpha_t \cdot C_t)$ 
3: -----
4:  $D_1(x) = 1/m$  {Initialize the weight distribution}
5: for  $t = \{1, 2, \dots, T\}$  do
6:    $C_t = \epsilon(D, D_t)$  {Create classifier  $C_t$ }
7:    $e_t = P_{x \sim D}(h_t(x) \neq f(x))$  {Calculate error  $e_t$ }
8:    $\alpha_t = \log \frac{1 - e_t}{e_t} + \log(K - 1)$  {Calculate the weight  $h_t$ }
9:    $D_t(x) \leftarrow D_t(x) \cdot \exp(\alpha_t \cdot P(C_t \neq f(x)))$  {Update the distribution  $D_t$ ,  $i = \{1, 2, \dots, m\}$ }
10:  Renormalize  $D_t(x)$ 
11: end for
```

---

---

**Algorithm 3 : Stagewise Additive Modeling for Real Value Predictions: SAMME.R**

---

```
1: // Input: Data Set  $D = \{(x_1, y_1), (x_2, y_2), \dots, (x_m, y_m)\}$ , Number of Learning Rounds  $T$ , Learning Algorithm  $\epsilon$ 
2: // Output:  $\text{sign}(\sum_{t=1}^T \alpha_t \cdot C_t)$ 
3: -----
4:  $D_1(x) = 1/m$  {Initialize the weight distribution}
5: for  $t = \{1, 2, \dots, T\}$  do
6:    $C_t = \epsilon(D, D_t)$  {Create classifier  $C_t$ }
7:    $p_{kt}(x) = \text{Prob}(y = k|x), k = \{1, 2, \dots, K\}$ 
8:    $h_{kt}(x) \leftarrow (K - 1)(\log p_{kt}(x) - \frac{1}{K} \cdot \sum_{k'} \log p_{k't}(x))$ 
9:    $D_t(x) \leftarrow D_t(x) \cdot \exp(\frac{1 - K}{K} \cdot y_i^T \cdot \log(p_t(x_i)))$  {Update the distribution  $D_t$ ,  $i = \{1, 2, \dots, m\}$ }
10:  Renormalize  $D_t(x)$ 
11: end for
```

---

and provide insight to the oncological expert during prognosis of future test subjects. Sample box plots have been displayed in Figures ?? to ??. The entire list of digital biomarkers along with their corresponding box plots have been included in the supplementary material. Note that the number of digital biomarkers correspond to the number of the box plots which in turn corresponds to number of features selected.

The pipeline developed for this study consists of multidisciplinary stages with involvement of both Radiomics and modern statistics. While Radiomics provides a real-world application based

---

**Algorithm 4** : Ensemble of Ensemble: SFORCE

---

```
1: // Input: Data Set  $D = \{(x_1, y_1), (x_2, y_2), \dots, (x_m, y_m)\}$ , Feature Set  $F$ , Randomization Factor  $R$ , Number of trees  
    $T$ , Number of Learning Rounds  $T'$ , Learning Algorithm  $\epsilon$   
2: // Output: Root node of  $i^{\text{th}}$  Boosted Tree  
3: -----  
4: Random Forest  
5: for  $\forall i \in \{1, 2, \dots, T\}$  do  
6:    $N_i \leftarrow$  Root node of  $i^{\text{th}}$  tree  
7:   if All targets belong to same class i.e  $y_i$  or  $F \in \emptyset$  then  
8:     Call SAMME.R with  $N_i$   
9:   end if  
10:   $D^i \leftarrow$  bootstrapped sample from  $D$   
11:  for Each node do  
12:     $f \leftarrow$  Randomly selected  $R$  features from  $F$   
13:     $N_f \leftarrow$  Best Feature from  $f$  features  
14:     $N_p \leftarrow$  Best Split based on  $N_f$   
15:    Call SAMME.R with  $N_i$   
16:  end for  
17: end for  
18: return  $N_i$   
19: -----  
20: SAMME/SAMME.R  
21:  $D_1(x) = 1/m$  {Initialize the weight distribution}  
22: for  $t = \{1, 2, \dots, T\}$  do  
23:    $C_t = \epsilon(D, D_t)$  {Create classifier  $C_t$ }  
24:    $p_{kt}(x) = \text{Prob}(y = k|x), k = \{1, 2, \dots, K\}$   
25:    $h_{kt}(x) \leftarrow (K - 1)(\log p_{kt}(x) - \frac{1}{K} \cdot \sum_k \log p_{k't}(x))$   
26:    $D_t(x) \leftarrow D_t(x) \cdot \exp(\frac{1 - K}{K} \cdot y_i^T \cdot \log(p_t(x_i)))$   $\{i = \{1, 2, \dots, m\}\}$   
27:   Renormalize  $D_t(x)$   
28:   Call Random Forest with  $(\sum_{t=1}^{T'} \alpha_t \cdot C_t)$   
29: end for
```

---

---

**Algorithm 5** DigiOnco: Algorithmic Flow



---

```
1: //Input Image dataset  $D_n$  and masks  $D_m$   
2: //Output Predicted Class  
3: for Each image  $i$  in  $D_n$  do  
4:   Convert image to a suitable format using conversion software  
5:   Call the pre-processing techniques on the formatted images  
6:   Using mask  $j$  for corresponding  $i$ , extract radiomics features  
7:   Create a grid of p-values  
8:   for EACH value in grid do  
9:     Call Algorithm 4 with related feature set  
10:  end for  
11:  Obtain accuracy levels and digital bio-markers  
12: end for
```

---

avenue, statistical tools were used to narrow down our biomarker search process. The aim of condensing the number of features is to preserve the features with the highest level information embedded in them.

However it must also be duely noted that this pipeline is quite delicate when it comes to producing results as the errors encountered in each step are rippled onto the next stages. Furthermore an increased sample dataset size could help further fine tune the model. Additional Deep Learning frameworks can also be introduced to provide competition to the incumbent design model.



### *3.1. Contributors*

Consortium-HCG served as a medical partner and provided the data. BMS College acted as a technical partner which analysed the data and obtained the results. All authors contributed to the writing of the final version of the Article.

### *3.2. Declaration of interests*

We declare no competing interests.

### *3.3. Data Sharing*

### *3.4. Acknowledgment*